Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

603.05INR
6:21am EDT
Change (% chg)

Rs-9.50 (-1.55%)
Prev Close
Rs612.55
Open
Rs615.40
Day's High
Rs617.65
Day's Low
Rs599.80
Volume
571,075
Avg. Vol
349,123
52-wk High
Rs854.50
52-wk Low
Rs572.40

Latest Key Developments (Source: Significant Developments)

Sun Pharma announces fda filing acceptance of Biologics License Application for tildrakizumab
8:03am EDT 

May 24 (Reuters) - Sun Pharmaceutical Industries Ltd : :Sun Pharma announces U.S. FDA filing acceptance of Biologics License Application (bla) for tildrakizumab.  Full Article

Sun Pharma says US FDA files acceptance of BLA for Tildrakizumab
12:55am EDT 

May 24 (Reuters) - Sun Pharmaceutical Industries Ltd :Says US FDA filing acceptance of biologics license application (BLA) for Tildrakizumab.Says Tildrakizumab is investigational IL-23P19 inhibitor evaluated for treatment of moderate-to-severe plaque psoriasis..  Full Article

Beijing Science Sun Pharmaceutical to pay div of 2.5 yuan/10 shares for 2016
Tuesday, 25 Apr 2017 10:47pm EDT 

April 26(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:* Says it will pay dividend of 2.5 yuan/10 shares for 2016.  Full Article

Hunan China Sun Pharma Machinery unit signs partnership framework agreement on gene detection project
Thursday, 20 Apr 2017 10:08pm EDT 

April 21(Reuters) - Hunan China Sun Pharma Machinery Co Ltd <300216.SZ> ::* Says its unit signed a partnership framework agreement with Changsha county local health bureau, to provide service for gene detection project for hypertensive patients .  Full Article

Hunan China Sun Pharma Machinery to pay annual cash div as 0.6 yuan per 10 shares for FY 2016
Wednesday, 19 Apr 2017 02:42am EDT 

April 19(Reuters) - Hunan China Sun Pharma Machinery Co Ltd <300216.SZ> : :* Says it plans to pay annual cash dividend as 0.6 yuan(pre-tax) per 10 shares as FY 2016 div payment.  Full Article

Hunan China Sun Pharma Machinery sees Q1 FY 2017 net profit up 0 to 30 pct
Tuesday, 11 Apr 2017 01:30am EDT 

Hunan China Sun Pharma Machinery Co Ltd <300216.SZ> : Sees Q1 FY 2017 net profit to increase by 0 to 30 percent, or to be 18.6 million yuan to 24.2 million yuan . Says Q1 FY 2016 net profit was 18.6 million yuan .The reason for the forecast is increased income of intelligent hybrid packing automatic production line.  Full Article

Beijing Science Sun Pharmaceutical sees FY 2017 Q1 net profit to decrease by 5 pct to 25 pct
Monday, 10 Apr 2017 02:30am EDT 

Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ> : Sees net profit for FY 2017 Q1 to decrease by 5 percent to 25 percent, or to be 44.1 million yuan to 61.8 million yuan, compared to net profit of FY 2016 Q1 (58.9 million yuan) .Says industry circulation policy as main reason for the forecast.  Full Article

Almirall says regulatory filing for Tildrakizumab in Europe is validated
Friday, 24 Mar 2017 02:57am EDT 

Almirall SA :The company and Sun Pharma announce validation of regulatory filing for Tildrakizumab, an antibody designed for treatment of moderate-to-severe plaque psoriasis, by the European Medicines Agency (EMA).  Full Article

Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall
Friday, 24 Mar 2017 12:53am EDT 

Sun Pharmaceutical Industries Ltd : Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall. . Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. .Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients.  Full Article

Sun Pharma Industries says Canadian unit to acquire Thallion Pharma
Friday, 17 Mar 2017 05:41am EDT 

Sun Pharmaceutical Industries Ltd : Says deal for c$2.3 million . Taro Pharmaceuticals Inc. (Canada) entered into deal to acquire all issued and outstanding shares of Thallion Pharma . Consideration would be in cash . Post deal, no turnover expected of existing products as all revenue-producing assets have been transferred from Thallion to Bellus Health . Post acquisition of Thallion, Taro Pharma would have only rights for development of orphan drug candidate, Shigamab .No material effect of acquisition by Taro Pharmaceuticals (Canada) on consol revenue, expenses or profits of co.  Full Article

More From Around the Web

BRIEF-Sun Pharma announces fda filing acceptance of Biologics License Application for tildrakizumab

* Sun Pharma announces U.S. FDA filing acceptance of Biologics License Application (bla) for tildrakizumab Source text for Eikon: Further company coverage: